Skip to main content

Table 1 Baseline patient characteristics of the included studies

From: A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms

References No. Sex (M/F) Median age (years, range) No. of PV No. of ET No. of PMF Thrombotic outcome Bleeding outcome Study period Type
Fenaux 1990 [7] 147 60/87 60 (18–83) 147 Yes (A + V) Yes 1970–1987 R
Colombi 1991 [8] 103 44/59 59 (9–88) 103 Yes (A + V) Yes 1975–1990 R
Besses 1999 [9] 148 53/95 60.5 (11–85) 148 Yes (A + V) Yes 1979–1994 R
Manoharan 1999 [10] 61 PV: 10/ 10
ET: 10/ 20
PMF: 5/ 6
PV: 76 (54–84)
ET: 71 (25–88)
PMF: 74 (31–84)
20 30 11 Yes (A + V) No 1993–1997 P
Jensen 2000 [11] 96 27/69 67 (18–87) 96 Yes (A + V) Yes 1977–1998 R
Passamonti 2000 [12] 163 98/65 57 (30–82) 163 Yes (A + V) Yes 1975–1997 R
Chim 2005 [13] 231 112/119 65 (18–90) 231 Yes (A + V) Yes NR R
Marchioli 2005 [14] 1638 942/ 696 60.4 1638 Yes (A + V) Yes NR P
Cervantes 2006 [15] 155 97/ 58 65 (17–89) 155 Yes (A + V) No 1972–2005 R
Wolanskyj 2006 [16] 322 104/ 218 54 (12–88) 322 Yes (A + V) Yes 1956–1992 R
Carobbio 2007 [17] 439 175/ 264 54 (10–93) 439 Yes (A + V) No 1981–2006 R
Vannucchi 2007 [18] 962 PV: 176/ 147
ET: 202/ 437
NR 323 639 Yes (A + V) No NR R
Bang 2009 [19] 283 143/ 140 61 120 NR NR Yes (A + V) Yes 2006–2007 P
Barbui 2010 [20] 707 465/ 242 62 (11–90) 707 Yes (A + V) No 1973–2008 R
Elliott 2010 [21] 205 131/ 74 62 (28–87) 205 Yes (A + V) No 1982–2008 R
Palandri 2011 [22] 532 205/ 327 64 (16–95) 532 Yes (A + V) No 1978–2008 R
Buxhofer-Ausch 2012 [23] 264 109/ 155 57.4 264 Yes (A + V) No NR P
Finazzi 2012 [24] 1104 ET: 370/ 521
PMF: 74/ 106
ET: 55.7 (12.9–91)
PMF: 57.4 (20.9–87.7)
891 180 No Yes NR P
Angona 2015 [25] 214 57/ 157 64 (9–93) 214 Yes (A + V) No 1985–2012 R
Enblom 2015 [26] 612 PV: 131/ 118
ET: 117/ 155
PMF: 47/ 44
PV: 69
ET: 67
PMF: 71
249 272 91 Yes (A + V) Yes 1995–2013 R
Lim 2015 [27] 102 54/ 48 64 (24–87) 33 69 Yes (A) Yes 2004–2012 R
Duangnapasatit 2015 [28] 157 PV: 46/ 22
ET: 32/ 51
PMF: 4/ 2
PV: 59.6 (18–88)
ET: 61.1 (21–89)
PMF: 68.3 (52–78)
68 83 6 Yes (A + V) Yes 2003–2013 R
Kaifie 2016 [29] 454 232/ 222 60 142 140 113 Yes (A + V) Yes NR P
Cerquozzi 2017 [30] 587 284/ 303 60 (17–94) 587 Yes (A + V) No NR P
Abdulkarim 2017 [31] 2389 PV: 548/557
ET: 534/750
PV: 69 (17–98)
ET: 68 (13–94)
1105 1284 Yes (A + V) Yes 2008–2015 R
Soyer 2017 [32] 708 PV: 132/ 81
ET: 151/ 239
PMF: 56/ 49
PV: 47.5 (17–86)
ET: 41.5 (17–89)
PMF: 69.5 (19–87)
213 390 105 Yes (A + V) Yes 1987–2014 R
Bertozzi 2017 [33] 253 NR NR 124 121 8 Yes (A) Yes 1978–2016 R
Zhou 2018 [34] 150 67/ 83 61 (41–71) 150 Yes (A + V) No 2013–2016 P
Hintermair 2018 [35] 250 152/ 98 NR NR NR NR Yes (A + V) No 2008–2015 R
  1. Abbreviations: A Artery, ET Essential thrombocythemia, F Female, M Male, NR Not reported, P Prospectively, PMF Primary myelofibrosis, PV Polycythemia vera, R Retrospectively, V Vein